1
Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial
Condition(s):Brain-dead Organ DonorsLast Updated:February 10, 2022Recruiting
Canrenoic Acid as an Intervention: 9 Clinical Trials
Hide Studies Not Open or Pending
2
Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.
Condition(s):COVID-19 PneumoniaLast Updated:June 8, 2021Recruiting
3
Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19
Condition(s):COVID-19 Acute Respiratory Distress SyndromeLast Updated:May 20, 2022Not yet recruiting
4
Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
Condition(s):ST-elevation Myocardial InfarctionLast Updated:October 26, 2016Completed
5
Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation.
Condition(s):Atrial Fibrillation, ParoxysmalLast Updated:May 25, 2018Unknown status
6
Safety and Efficacy of Early, seQUential Oral dIuretic Nephron blockAde In Acute Heart Failure
Condition(s):Acute Heart FailureLast Updated:August 20, 2019Not yet recruiting
7
Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
Condition(s):Cirrhosis; AscitesLast Updated:September 25, 2008Completed
8
Aldosterone Blockade Early After Acute Myocardial Infarction
Condition(s):Myocardial InfarctionLast Updated:June 11, 2015Completed
9
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
Condition(s):Acute Heart Failure; Diuretics Drug ReactionsLast Updated:June 15, 2022Recruiting